Real-world safety of switching from originator to biosimilar natalizumab

被引：0
|
作者：
Brustad, Age Winje [1 ]
Hogestol, Einar [2 ,3 ,4 ]
Meling, Martine [2 ]
Celius, Elisabeth Gulowsen [2 ,4 ]
Berg-Hansen, Pal [2 ]
Konig, Marton [2 ,4 ]
Holterbakken, Trine Alm [2 ]
Warren, David [1 ]
Gehin, Johanna [1 ]
Bolstad, Nils [1 ]
Nygaard, Gro Owren [2 ,4 ]
机构：
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[3] Oslo Univ Hosp, Dept Psychol, Oslo, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1670/563
引用
收藏
页码：1056 / 1057
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
  • [2] Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar
    Kay, Jonathan
    Doerner, Thomas
    Emery, Paul
    Kvien, Tore K.
    Breedveld, Ferdinand C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (04) : E44 - +
  • [3] REAL-WORLD EXPERIENCE ON SWITCHING ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN INFLAMMATORY ARTHRITIS - A RETROSPECTIVE STUDY
    Yeoh, S. A.
    Saxby, K.
    Barron, A.
    Moore, S.
    Gani, S.
    Ehrenstein, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1458 - 1458
  • [4] Switching from natalizumab to alemtuzumab in patients with RRMS: real-world experience
    Fortin, J.
    Jacques, F. H.
    Fokko, V. Sikati
    Grand'Maison, F.
    Emond, F.
    Bakdache, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 783 - 783
  • [5] Patient perspectives from a real-world adalimumab biosimilar switching program
    Choon, X. Y.
    Moore, A.
    Sharma, E.
    Anderson, S.
    Gecse, K.
    Mawdsley, J.
    Ray, S.
    Dart, R.
    Irving, P.
    Samaan, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1761 - i1761
  • [6] Using real-world data to evaluate biosimilar switching
    Dutcher, Sarah K.
    Eworuke, Efe
    Blum, Michael D.
    Ball, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (07) : 814 - 816
  • [7] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    Indian Journal of Gastroenterology, 2022, 41 : 446 - 455
  • [8] Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
    Jose Casanova, Maria
    Nantes, Oscar
    Varela, Pilar
    Vela-Gonzalez, Milagros
    Rivero, Montserrat
    Sierra-Gabarda, Olivia
    Riestra, Sabino
    Barreiro-de Acosta, Manuel
    del Mar Martin-Rodriguez, Maria
    Jerusalen Gargallo-Puyuelo, Carla
    Reygosa, Cristina
    Munoz, Roser
    Garcia de la Filia-Molina, Irene
    Nunez-Ortiz, Andrea
    Kolle, Lilyan
    Calafat, Margalida
    Maria Huguet, Jose
    Iglesias-Flores, Eva
    de Jesus Martinez-Perez, Teresa
    Bosch, Orencio
    Maria Duque-Alcorta, Jose
    Frago-Larramona, Santiago
    Van Domselaar, Manuel
    Manuel Gonzalez-Cosano, Victor
    Bujanda, Luis
    Rubio, Saioa
    Mancebo, Alejo
    Castro, Beatriz
    Garcia-Lopez, Santiago
    de Francisco, Ruth
    Nieto-Garcia, Laura
    Laredo, Viviana
    Gutierrez-Casbas, Ana
    Mesonero, Francisco
    Leo-Carnerero, Eduardo
    Canete, Fiorella
    Ruiz, Lucia
    Gros, Beatriz
    del Moral-Martinez, Maria
    Rodriguez, Cristina
    Chaparro, Maria
    Gisbert, Javier P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (01) : 60 - 70
  • [9] Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
    Nielsen, Valdemar Wendelboe
    Lund, Tamara Theresia
    Gniadecki, Robert
    Olsen, Rasmus Huan
    Nissen, Christoffer Valdemar
    Schwensen, Jakob Ferlov Baselius
    Thomsen, Simon Francis
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [10] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Kumar, Peeyush
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Kedia, Saurabh
    Sahu, Pabitra
    Ranjan, Mukesh Kumar
    Mundhra, Sandeep
    Golla, Rithvik
    Kumar, Mukesh
    Virmani, Shubi
    Gupta, Anvita
    Yadav, Nidhi
    Makharia, Govind
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) : 446 - 455
12345